Vivo PANDA is a new, life science-focused venture fund

Vivo CapitalVivo PANDA is a new, $100 million plus venture fund created to invest primarily in innovative early stage healthcare companies across a broad spectrum, but with a particular focus on pharmaceuticals, biotechnology, medical devices, and diagnostics. Read more about the new fund here.

Tom Ballard

By Tom Ballard, Chief Alliance Officer,
Pershing Yoakley & Associates. P.C.

eNews & Updates

Sign up to receive posts via email.

Connect With Us

Upcoming Events

Links to Partners